VGX-3100
Phase 2Biologic
Inovio PharmaceuticalsVGX-3100 is one of 76 biologic programs targeting Cervical Intraepithelial Neoplasia Grade 2/3. It is currently in Phase 2.
3
Indications
7
Total Trials
0
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
296 competitors in Immunodeficiency
#DrugCompanyPhaseTrials
1Cabenuva
GSKPhase 3
Sovaldi
GileadPhase 3
Farxiga
AstraZenecaPhase 3
Viread
GileadPhase 3
Retrovir
BBp Consulting, Inc
Phase 3
Prezista
WWim Janssens
Phase 3
Valtrex
GGlaxo Dba Glaxosmithkline
Phase 3
BIC/FTC/TAF
Merck & Co.Phase 3
DTG/3TC
GSKPhase 3
Pegifn/rbv
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Papilloma2 trials
Treatment2 trials
Cervical Intraepithelial Neoplasia Grade 2/31 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VGX-3100. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company